In late May, Pfizer and BioNTech jointly announced their vaccine for children six months to four years old to appear to have an 80 percent effectiveness preventing symptomatic infections. Their announcement is based upon the early analysis of data from their study. They will complete their submission in advance of the scheduled June 15 review by the Food and Drug Administration.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
Please log in to continue |